HOME
Vol , Issue
Date of Publication: April 01, 2004
DOI: https://doi.org/10.20529/IJME.2004.036
Views
, PDF Downloads:
Correspondence
The author defends
Abstract:
'How many people know that eight patients in Hyderabad who were administered recombinant streptokinase to test its efficacy and safety have died? According to the Genetic Engineering Approval Committee (GEAC), the trial was being conducted by the drug's manufacturer Shantha Biotechnics without taking clearance. Not surprisingly, the Company denies the allegation claiming that it had taken permission from the DCGI.
Copyright and license ©Indian Journal of Medical Ethics 2016: Open Access and Distributed under the Creative Commons license ( CC BY-NC-ND 4.0), which permits only non-commercial and non-modified sharing in any medium, provided the original author(s) and source are credited.
